SVB Leerink Starts Rapt Therapeutics (RAPT) at Outperform

SVB Leerink analyst Thomas Smith initiates coverage on Rapt Therapeutics (NASDAQ: RAPT) with a Outperform rating and a price target of $49.00.

For an analyst ratings summary and ratings history on Rapt Therapeutics click here. For more ratings news on Rapt Therapeutics click here.

Shares of Rapt Therapeutics closed at $33.07 yesterday.

You May Also Be Interested In

• B.Riley Starts Energy Fuels (UUUU) at Buy
• Oppenheimer Starts Sprout Social Inc. (SPT) at Outperform, 'Owning the Category's Socialite'
• Jones Trading Starts Rezolute (RZLT) at Buy, 'an under-appreciated player in the rare disease space'